Table 1 The clinical characteristics of eligible breast cancer patients in the primary and validation cohort
Training Cohort | Validation Cohort | |||||
|---|---|---|---|---|---|---|
Clinical Features | non-SLN (Pos) (n = 182) | non-SLN (Neg) (n = 436) | P value | non-SLN (Pos) (n = 163) | non-SLN (Neg) (n = 369) | P value |
Age (years) | 53.9 ± 10.3 | 58.2 ± 12.7 | 0.216 | 54.4 ± 13.1 | 57.5 ± 12.9 | 0.326 |
No. of tumor lesions | < 0.001 | < 0.001 | ||||
Single | 166 (91.2%) | 425 (97.5%) | 149 (91.4%) | 363 (98.4%) | ||
Multiple | 16 (8.8%) | 11 (2.5%) | 14 (8.6%) | 6 (1.6%) | ||
Tumor grade | 0.012 | < 0.001 | ||||
G1 | 12 (6.6%) | 54 (12.4%) | 9 (5.5%) | 57 (15.4%) | ||
G2/G3 | 170 (93.4%) | 382 (87.6%) | 154 (94.5%) | 312 (84.6%) | ||
Histological type | 0.897 | 0.912 | ||||
IDC | 171 (94.0%) | 407 (93.3%) | 146 (89.6%) | 334 (90.5%) | ||
Other | 11 (6.0%) | 28 (6.7%) | 17 (10.4%) | 35 (9.5%) | ||
T stage | 0.037 | 0.082 | ||||
T1/T2 | 93 (51.1%) | 262 (60.1%) | 87 (53.4%) | 219 (59.4%) | ||
T3/T4 | 89 (48.9%) | 174 (39.9%) | 76 (46.6%) | 150 (40.6%) | ||
No. of positive SLN | < 0.001 | < 0.001 | ||||
1 | 118 (64.8%) | 325 (74.5%) | 75 (46.0%) | 314 (85.1%) | ||
2 | 64 (35.2%) | 111 (25.5%) | 88 (54.0%) | 55 (14.9%) | ||
No. of negative SLN | ||||||
0 | 31 (17.0%) | 17 (3.9%) | < 0.001 | 23 (14.1%) | 19 (5.2%) | < 0.001 |
1 | 55 (30.2%) | 68 (15.6%) | 45 (27.6%) | 54 (14.6%) | ||
≥2 | 96 (52.8%) | 351 (80.5%) | 95 (58.3%) | 296 (80.2%) | ||
LVI | < 0.001 | 0.001 | ||||
No | 128 (70.3%) | 353 (81.0%) | 114 (69.9%) | 287 (77.8%) | ||
Yes | 54 (29.7%) | 83 (19.0%) | 49 (30.1%) | 82 (22.2%) | ||
ER | 0.236 | 0.352 | ||||
Negative | 51 (28.0%) | 132 (30.3%) | 49 (30.1%) | 122 (33.1%) | ||
Positive | 131 (72.0%) | 304 (69.7%) | 114 (69.9%) | 247 (66.9%) | ||
PR | 0.593 | 0.751 | ||||
Negative | 52 (28.6%) | 138 (31.7%) | 37 (22.7%) | 97 (26.3%) | ||
Positive | 130 (71.4%) | 298 (68.3%) | 126 (77.3%) | 272 (73.7%) | ||
HER-2/neu | 0.683 | 0.448 | ||||
Negative | 37 (20.3%) | 83 (19.0%) | 32 (19.6%) | 81 (22.0%) | ||
Positive | 145 (79.7%) | 353 (81.0%) | 131 (80.4%) | 288 (78.0%) | ||
Ki-67 | 0.912 | 0.836 | ||||
< 14 | 46 (25.3%) | 110 (25.2%) | 41 (25.2%) | 89 (24.1%) | ||
≥14 | 136 (74.7%) | 326 (74.8%) | 122 (74.8%) | 280 (75.9%) | ||
CA 125 | 0.839 | 0.910 | ||||
Negative | 164 (90.1%) | 387 (88.8%) | 139 (85.3%) | 329 (89.2%) | ||
Positive | 18 (9.9%) | 49 (11.2%) | 24 (14.7%) | 40 (10.8%) | ||
CA 15–3 | < 0.001 | < 0.001 | ||||
Negative | 126 (69.2%) | 416 (95.4%) | 122 (74.8%) | 339 (91.9%) | ||
Positive | 56 (30.8%) | 20 (4.6%) | 41 (25.2%) | 30 (8.1%) | ||
CEA | < 0.001 | < 0.001 | ||||
Negative | 159 (87.4%) | 414 (95.0%) | 138 (84.7%) | 350 (94.9%) | ||
Positive | 23 (12.6%) | 22 (5.0%) | 25 (15.3%) | 19 (5.1%) | ||